Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study.
Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M; GETECCu (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Loras C, et al. Among authors: saro c. Am J Gastroenterol. 2009 Jan;104(1):57-63. doi: 10.1038/ajg.2008.4. Am J Gastroenterol. 2009. PMID: 19098850
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.
Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M; REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group. Loras C, et al. Among authors: saro c. Gut. 2010 Oct;59(10):1340-6. doi: 10.1136/gut.2010.208413. Epub 2010 Jun 24. Gut. 2010. PMID: 20577000
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, Gomollón F, Rodrigo L, Calvet X, Esteve M, García-Planella E, García-López S, Taxonera C, Calvo M, López M, Ginard D, Gómez-García M, Garrido E, Pérez-Calle JL, Beltrán B, Piqueras M, Saro C, Botella B, Dueñas C, Ponferrada A, Mañosa M, García-Sánchez V, Maté J, Gisbert JP. Casanova MJ, et al. Among authors: saro c. Am J Gastroenterol. 2013 Mar;108(3):433-40. doi: 10.1038/ajg.2012.430. Epub 2013 Jan 15. Am J Gastroenterol. 2013. PMID: 23318480
Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.
Castaño-Milla C, Chaparro M, Saro C, Barreiro-de Acosta M, García-Albert AM, Bujanda L, Martín-Arranz MD, Carpio D, Muñoz F, Manceñido N, García-Planella E, Piqueras M, Calvet X, Cabriada JL, Botella B, Bermejo F, Gisbert JP. Castaño-Milla C, et al. Among authors: saro c. J Clin Gastroenterol. 2015 Jan;49(1):34-40. doi: 10.1097/MCG.0000000000000169. J Clin Gastroenterol. 2015. PMID: 25485513
Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study.
Alonso A, Domènech E, Julià A, Panés J, García-Sánchez V, Mateu PN, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Manyé J, Cabré E, López-Lasanta M, Tortosa R, Gelpí JL, García-Montero AC, Bertranpetit J, Absher D, Myers RM, Marsal S, Gisbert JP. Alonso A, et al. Among authors: saro c. Gastroenterology. 2015 Apr;148(4):794-805. doi: 10.1053/j.gastro.2014.12.030. Epub 2014 Dec 31. Gastroenterology. 2015. PMID: 25557950
Long-term durability of response to adalimumab in Crohn's disease.
Chaparro M, Panés J, García V, Merino O, Nos P, Domènech E, Peñalva M, García-Planella E, Esteve M, Hinojosa J, Andreu M, Muñoz F, Gutiérrez A, Mendoza JL, Barrio J, Barreiro-de M, Vera I, Vilar P, Cabriada JL, Montoro MA, Aldeguer X, Saro C, Gisbert JP. Chaparro M, et al. Among authors: saro c. Inflamm Bowel Dis. 2012 Apr;18(4):685-90. doi: 10.1002/ibd.21758. Epub 2011 May 25. Inflamm Bowel Dis. 2012. PMID: 21618353
Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
R-Grau Mdel C, Chaparro M, Mesonero F, Barreiro-de Acosta M, Castro L, Castro M, Domènech E, Mancenido N, Pérez-Calle JL, Taxonera C, Barrio J, De Francisco R, Fernández-Salgado E, Luzón L, Merino O, Oltra L, Saro C, Bermejo F, García-Sánchez V, Ginard D, Gutiérrez A, Vera I, Antón R, Ber Y, Calvet X, Gisbert JP. R-Grau Mdel C, et al. Among authors: saro c. Dig Liver Dis. 2016 Jun;48(6):613-9. doi: 10.1016/j.dld.2016.02.012. Epub 2016 Mar 2. Dig Liver Dis. 2016. PMID: 26992847
Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Chaparro M, et al. Among authors: saro c. Inflamm Bowel Dis. 2013 Jun;19(7):1404-10. doi: 10.1097/MIB.0b013e318281f28f. Inflamm Bowel Dis. 2013. PMID: 23665964
66 results